Minhua Wang, Qingqing Ding, Jun Gu, Steven M Sfamenos, Lei Huo, Zhenya Tang, Hongxia Sun, Melissa Robinson, Guilin Tang, Bora Lim, Yun Wu, Constance T Albarracin, Aysegul A Sahin, Hui Chen
BACKGROUND: Breast cancer with fluorescence in situ hybridization (FISH) group 2 pattern (HER2 <4 and HER2/CEP17 ratio ≥2, a subset of monosomy CEP17) was historically considered HER2-positive, but mostly HER2-negative according to updated 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines unless 3+ by immunohistochemistry (IHC). Therapeutic relevance of this group remained elusive, therefore we assessed if repeat IHC and FISH can assist final HER2 classification...
February 12, 2023: Clinical Breast Cancer